Lenalidomide For Multiple Myeloma

Lenalidomide is a derivative of the notorious anti-nausea drug Thalidomide, but does not share the same toxicity of Thalidomide. Recent data shows that Lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma (MM). In this study, at a median follow-up of 34 months, only 37 % of patients who received Lenalidomide had disease progression or had died, while 58 % of the patients who received placebo had disease progression or had died. Furthermore, the median time to disease progression was 46 months for the Lenalidomide group but only 27 months in the placebo group. I like this study because it shows the potential of off-label drug use.

Lenalidomide After Stem-Cell Transplantation For Multiple Myeloma.

Speak Your Mind